AgingResearch.NewsJoin free
medRxiv

Rare gene variants linked to benign fat and uterine tumors

People carrying disabling variants in TERF1, a chromosome-protection gene, had 3.32 times the odds of benign fatty tumors compared with people without those variants.

Paper by Benjamin D Lin, Karly Hoi-Lam Chan, Zheyang Zhang, +6 more authorsMinggui Pan · Stanford University School of Medicine
A uterus with rounded fibroids narrowing its cavity sits beside a smaller uterus without fibroids and a lobulated cluster of fat cells.

Our read

Populations
Studied:
Preprint: genetic association study of UK Biobank participants, against people without disabling TERF1 variants
What changed:
People with disabling TERF1 variants had 3.32 times the odds of benign fatty tumors compared with people without those variants
The catch:
Sarcoma outcomes relied on self-reports
In the record:
The 8th paper on POT1 with results in people; 52 on record in all.
Why it’s aging research:
It bears on staying healthy in midlife and later life.

Editor of record: Boris Djordjevic · AgingResearch.News

Paper
Follow @agingbrief

UK Biobank participants were studied in an observational genetic analysis of rare variants in five shelterin genes. These genes encode proteins that protect chromosome ends.

Variants that disrupted shelterin function were associated with lipomas, benign fatty tumors, and uterine leiomyomas, also called fibroids. Lipoma associations involved three genes. Fibroid associations involved all four core shelterin genes and were strongest for POT1, another chromosome-protection gene, with an odds ratio of 2.23 for carriers versus noncarriers. A second analysis pipeline reproduced associations for two shelterin genes. Neither of the tested gene groups was associated with self-reported sarcoma, a cancer of connective tissues.

Why it matters

Cancer risk is an important question in aging biology. This work examined whether tumor risks linked to chromosome-end protection extended beyond a previously studied group enriched for sarcoma cases.

Caveats

The sarcoma analysis relied on self-reports, and the authors said sarcoma-specific risk remained untested. The report is a preprint and has not been peer-reviewed.

Where the evidence stands

Telomerase and telomere maintenance

Cells: replicated by independent labs. Worms or flies, mice and humans: a single group.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

Includes the processes named after it and trials of drugs aimed at it.

  • 86 independent labs in 25 countries
  • 1 finding against
  • Funders: National Institutes of Health and others
  • 19 of 116 findings with company ties

Comments

Be the first to comment.

More on Telomerase and telomere maintenance